The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...

The Trump administration decided to put the pilot on hold until at least 2027.

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

The Centers for Medicare and Medicaid Services (CMS) is rolling out a program this summer that will provide more affordable ...

The pathway is designed to reduce the delay between FDA authorization and Medicare coverage for certain Class II and Class ...

The Centers for Medicare & Medicaid Services has postponed its BALANCE pilot program for GLP‑1 obesity drug coverage until at least 2027 after insurers balked at costs and risks. In its place, CMS ...

The US Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) have proposed a parallel ...

On April 14, 2026, the Centers for Medicare and Medicaid Services (“CMS”) published a proposed rule that would require faster ...

The Centers for Medicare & Medicaid Services (CMS) has postponed its BALANCE program, intended to integrate obesity drugs into Medicare Part D, to January 2027 after failing to secure sufficient ...

Explore hospital strategies winning under CMS value-based payment models to succeed with mandatory bundles and accountable care structures.

The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to ...

Minnesota's Medicaid spending across 14 programs more than doubled in five years, leading to fraud concerns and state action.